Todos Medical receives new FDA Certificate of Free Sale for its Tollovid Daily immune system support

Todos Medical Ltd has reported that the US Food and Drug Administration (FDA) has granted a new Certificate of Free Sale for Tollovid Daily, the newest member of the company’s Tollovid dietary supplement product line. The company said the certificate is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim. Each 60-pill bottle of Tollovid Daily can help support and maintain healthy immune function for 30 days.  Todos said it intends to establish a monthly subscription model as part of its marketing launch campaign for Tollovid Daily immune system support. Tollovid and Tollovid Daily are both 3CL protease inhibitor products developed under a joint venture with NLC Pharma. READ: Todos Medical to launch cPass SARS-CoV-2 neutralizing antibody detection kit “We are very excited with the new FDA Certificate of Free Sale for Tollovid Daily, the newest member of our Tollovid dietary supplement product line,” said Todos CEO Gerald Commissiong in a statement. “Given our strong belief that in today’s world 3CL protease inhibition is critical to supporting and maintaining healthy immune function, we are extremely pleased that the FDA viewed the in vitro data presented as sufficient to allow this claim. With the global market for immune support supplements expected to grow from $18 billion in 2020 to over $31 billion by 2028 according to Fortune Business Insights, we are confident that our Tollovid products are well positioned to tap into this lucrative, growing market opportunity.” Commissiong added: “Going forward, we are focused on building our infrastructure for a planned US marketing launch of Tollovid Daily now that we have completed building our base www.MyTollovid.com e-commerce infrastructure. We are working on getting Tollovid approved for distribution on large e-commerce platforms that can fulfill rapidly for both individuals and resellers.” The first commercial production run of Tollovid is now available for purchase at www.MyTollovid.com and Tollovid Daily is expected to be available beginning in late August.  The company said it expects Tollovid product line revenue to become material for its earnings in the fourth quarter of 2021. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham